SYMBOLLON CORP
10QSB, EX-27.1, 2000-08-10
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: SYMBOLLON CORP, 10QSB, 2000-08-10
Next: CUBIST PHARMACEUTICALS INC, 8-K, 2000-08-10



<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
CONDENSED UNAUDITED FINANCIAL STATEMENT OF SYMBOLLON CORPORATION FOR THE SIX
MONTHS ENDED JUNE 30, 2000 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE
TO SUCH FINANCIAL STATEMENT AS FILED IN THE FORM 10-QSB.
</LEGEND>
<MULTIPLIER>                                  1

<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                              DEC-31-2000
<PERIOD-START>                                 JAN-01-2000
<PERIOD-END>                                   JUN-30-2000
<CASH>                                         2,455,235
<SECURITIES>                                           0
<RECEIVABLES>                                     21,870
<ALLOWANCES>                                           0
<INVENTORY>                                       95,926
<CURRENT-ASSETS>                               2,649,642
<PP&E>                                           269,055
<DEPRECIATION>                                   177,632
<TOTAL-ASSETS>                                 3,017,471
<CURRENT-LIABILITIES>                            509,909
<BONDS>                                                0
                            175,000
                                            0
<COMMON>                                           3,602
<OTHER-SE>                                     2,332,562
<TOTAL-LIABILITY-AND-EQUITY>                   3,017,471
<SALES>                                           81,400
<TOTAL-REVENUES>                                  81,400
<CGS>                                             63,767
<TOTAL-COSTS>                                          0
<OTHER-EXPENSES>                                 388,990
<LOSS-PROVISION>                                       0
<INTEREST-EXPENSE>                                     0
<INCOME-PRETAX>                                 (530,651)
<INCOME-TAX>                                           0
<INCOME-CONTINUING>                             (530,651)
<DISCONTINUED>                                         0
<EXTRAORDINARY>                                        0
<CHANGES>                                              0
<NET-INCOME>                                    (530,651)
<EPS-BASIC>                                         (.14)
<EPS-DILUTED>                                       (.14)




</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission